Literature DB >> 11369431

HIV fusion and its inhibition.

C C LaBranche1, G Galasso, J P Moore, D P Bolognesi, M S Hirsch, S M Hammer.   

Abstract

Mesh：

Substances：

Year:  2001        PMID： 11369431     DOI： 10.1016/s0166-3542(01)00130-9

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   5.970


× No keyword cloud information.
  19 in total

1.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells.

Authors:  Thomas J Ketas; Ines Frank; Per Johan Klasse; Brian M Sullivan; Jason P Gardner; Catherine Spenlehauer; Mirjana Nesin; William C Olson; John P Moore; Melissa Pope
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

3.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

4.  HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells.

Authors:  Jennifer M Pfaff; Craig B Wilen; Jessamina E Harrison; James F Demarest; Benhur Lee; Robert W Doms; John C Tilton
Journal:  J Virol       Date:  2010-04-21       Impact factor: 5.103

Review 5.  Targeting protein-protein interactions by rational design: mimicry of protein surfaces.

Authors:  Steven Fletcher; Andrew D Hamilton
Journal:  J R Soc Interface       Date:  2006-04-22       Impact factor: 4.118

6.  Design of an Escherichia coli expressed HIV-1 gp120 fragment immunogen that binds to b12 and induces broad and potent neutralizing antibodies.

Authors:  Sanchari Bhattacharyya; Pranveer Singh; Ujjwal Rathore; Mansi Purwar; Denise Wagner; Heather Arendt; Joanne DeStefano; Celia C LaBranche; David C Montefiori; Sanjay Phogat; Raghavan Varadarajan
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

7.  Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Authors:  Qi Guo; Hsu-Tso Ho; Ira Dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

8.  Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion.

Authors:  Samvel R Mkrtchyan; Ruben M Markosyan; Michael T Eadon; John P Moore; Gregory B Melikyan; Fredric S Cohen
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

9.  Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.

Authors:  Zhi Qi; Weiguo Shi; Na Xue; Chungen Pan; Weiguo Jing; Keliang Liu; Shibo Jiang
Journal:  J Biol Chem       Date:  2008-07-28       Impact factor: 5.157

10.  Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.

Authors:  Stefano Menzo; Antonella Castagna; Alessia Monachetti; Hamid Hasson; Anna Danise; Elisabetta Carini; Patrizia Bagnarelli; Adriano Lazzarin; Massimo Clementi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.